Veeva Systems VEEV

Technology · Software - Application · Synthos Deep Dive · 2026-07-03

$276.69

Buy — Core

—

The Overview

Veeva makes the software that nearly every drug company runs its business on — tracking sales reps, running clinical trials, and keeping regulators happy. It is a bit like the "Salesforce for the pharmaceutical industry," except Veeva only serves life sciences, and it dominates that niche. The business is excellent: it keeps about 75 cents of gross profit on every sales dollar, has more cash than debt, and more than 1,500 customers who rarely leave.

The catch: Veeva used to grow very fast, and now it grows at a more ordinary mid-teens pace. The stock got punished hard for that — it fell from about $310 to $193 — so today you can buy a great company at a much more reasonable price than a year ago. Our verdict is Buy — Tactical: worth owning as a smaller, opportunistic position, not a big anchor holding.

Here's what our three scores mean in everyday terms:

Downside Risk 4/10 (fairly safe). The company has no debt and a pile of cash, and the stock doesn't swing more than the market — but it has already shown it can fall a long way when growth disappoints.
Growth Quality 8/10 (very good). Steady, highly profitable, subscription-based, and extremely hard for a rival to dislodge.
Exponential Potential 4/10 (modest). It should keep growing nicely, but the easy land-grab is over; the newer AI "agent" products are the only thing that could re-accelerate it.

The one big worry: Veeva has already sold its main sales-rep software to most of the big drug companies, so future growth depends on selling newer products (clinical-trial and AI tools) — and if those stall, the mid-teens growth could slip further.

Putting a number on it: our fair-value estimate is $235 against a current price of $276.69 — a premium price for a business we still like.

Target entry zone $208 – $277 accumulate in this band; ideal adds on a dip toward the 50-day average near $208

Our summary metrics

Downside Risk (lower = safer)4/10Moderate

Fortress net-cash balance sheet & beta 0.95, but 21× fwd on a ~12% grower and a −43% drawdown show it can de-rate hard.

Growth Quality8/10Very High

~12% fwd rev & EPS CAGR, 75% gross margin, subscription-led, near-monopoly moat — quality is high but growth has cooled to mid-teens.

Exponential Potential4/10Moderate

Vertical-SaaS monopoly with a real AI-agent optionality leg, but growth is decelerating and the core CRM TAM is largely penetrated.

Fair value$235 $150–$300

What does “fair value” mean?

Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.

The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

Exponential Potential

Exponential Potential4/10Moderate

Vertical-SaaS monopoly with a real AI-agent optionality leg, but growth is decelerating and the core CRM TAM is largely penetrated.

What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.

Deeper analysis

Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.

Check our number Market-implied growth ≈ 29%/yr This isn’t how we calculate fair value — it’s public math you can verify yourself. To justify today’s $277, earnings would have to compound roughly 29% a year for 10 years (9% discount rate). Analysts forecast ~17%/yr, so the market is pricing in MORE than what the Street expects.

Reference table

Street consensus	$235.38 (high $320 / low $165; 29 Buy · 13 Hold · 1 Sell) — context, not our anchor
Valuation	33× trailing GAAP EPS · ~21× FY27E non-GAAP · ~19× FY28E · ~15× FY30E · EV/S 8.9× · EV/EBITDA 22.7×
Technicals	Repairing a downtrend — $193, −37% off the 52-wk high, below the 200-DMA, above the 50-DMA, RSI 75 (hot short-term bounce)
Conviction	Low — 1 net-bullish voice, +0.6 net, 1 reconciled claim. This is a quant/fundamentals call, not a conviction-panel call
Position sizing	Tactical/satellite, ~2–3% — a quality name bought on a de-rating, not a core anchor

What the experts actually said 1 traceable claims on VEEV · showing the highest-conviction voices

“Invert customer feedback: customers calling a healthcare CRM a 'bad idea' while not loving their current tool signaled opportunity (all four became Veeva clients).”

Invest Like the Bestbullishconviction 602022-07-04invest_like_the_best-7Gy-6nWAeZA:2188e58cce

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 75.

MACD 12 / 26 / 9 · trend & momentum

The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago

Solid = VEEV · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$276.69

Market cap$45B

P/E trailing44×

P/E FY26E / FY27E35× / 31×

EV / Sales11.1×*

EV / EBITDA28.0×*

Gross margin74.9%

Net margin29.3%

Dividend yield0.00%

Beta0.922

52-wk range$151 – $306

RSI(14)72

50 / 200-DMA$208 / $199

12-mo return+-6% (SPY +19%)

Street target$290 ($165–$330)

Analyst grades29 Buy · 13 Hold · 1 Sell

FMP ratingA-

Next earnings2026-09-02 (Q2 FY27 earnings; Street EPS est $2.22, rev ~$905M)

* Enterprise value recomputed in-house: the data vendor nets cash but omits short-term investments, overstating EV for cash-rich balance sheets. EV multiples marked * use market cap + total debt − cash − short-term investments.

1. What it is

Veeva Systems (NYSE: VEEV) is the dominant vertical-SaaS provider to the global life-sciences industry — cloud software, data, and (increasingly) AI built exclusively for pharma, biotech, and medical-device companies. Founded 2007, IPO 2013, HQ Pleasanton CA, led by founder-CEO Peter Gassner. It is structured as a Public Benefit Corporation. Fiscal year ends January 31 (so "FY27" is the year ending Jan-2027).

Two product families:

Veeva Commercial Cloud — CRM (the historical core, now migrating to Veeva's own Vault CRM after leaving the Salesforce platform), plus data/analytics (OpenData, Link, Crossix, Data Cloud) and marketing/engagement tools.
Veeva Development Cloud (Vault R&D) — cloud content and data management for clinical trials, regulatory, quality, and safety. This is the faster-growing, larger long-term opportunity.

Revenue mix (FY26, ending Jan-2026, from filings):

By type: Subscription services ~$2.55B (≈80%) · Professional services ~$0.65B (≈20%). Subscription is the high-margin, sticky recurring core. (FMP's FY26 product segmentation only itemizes the Commercial Cloud lines cleanly; the FY25 breakout showed R&D subscription $1.18B roughly equal to Commercial subscription $1.10B — Vault R&D has caught up to Commercial in size.)
By geography (FY26): North America $1.90B (60%) · Europe $0.94B (29%) · Asia-Pacific $0.28B (9%). US/North-America-centric but genuinely global, with Europe the fastest large region.

The strategic pivot management keeps returning to is AI agents: the Ostro acquisition (conversational AI for 50+ brands), Vault AI rolling across all Vault apps, and Veeva Falcon (agentic labor for clinical/regulatory/safety, early-adopter release planned November 2026). CEO Gassner frames it as moving "from an industry-specific application company to an industry-specific application and AI agent company" (§9).

2. The expert thesis — what the KB actually says (traceable)

Honest breadth disclosure: the Synthos knowledge base contains exactly ONE claim on VEEV. This is not a broad-panel conviction name like our flagship compounders. The verdict here is fundamentals- and quant-driven, and the one expert voice is corroborating color, not the load-bearing thesis.

The one claim — Invest Like the Best (invest_like_the_best-7Gy-6nWAeZA:2188e58cce, bullish, conviction 60, skill 1.0, dated 2022-07-04): the origin-story insight that Veeva's founding thesis came from inverting customer feedback — prospects called a healthcare-specific CRM "a bad idea" while simultaneously not loving their existing tools, which signaled a real unmet need (all four skeptics later became Veeva clients). This is a product/customer-insight and vertical-SaaS moat observation, and it captures why Veeva's wedge into the industry was durable.

What this claim does and does not support. It supports the moat leg of the thesis (deep vertical focus, customer capture) — which the financials corroborate. It is four years old (2022) and says nothing about today's valuation, the growth deceleration, or the AI-agent transition. So we lean on the quant/fundamental case: near-monopoly economics, net-cash balance sheet, and a valuation that has finally come back to earth. We do not manufacture a panel that isn't there — breadth is 1, net conviction +0.6, and the verdict below reflects that.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	4 · Low-Moderate	Net-cash (~$1.3B net cash, zero financial debt), beta 0.95, current ratio 4.7 — financially fortress-like. But it just proved it can shed 43% peak-to-trough on a growth scare, and 21× forward still isn't cheap for ~12% growth.
Growth Quality	8 · High	~12% forward revenue & non-GAAP EPS CAGR, 75% gross margin, ~80% recurring subscription revenue, ROIC ~10% and rising, near-monopoly switching costs. Elite for durability; a notch below the very best only because growth has cooled to mid-teens.
Exponential Potential	4 · Modest	Growth is decelerating (16% now vs 25%+ in the hypergrowth years) and the core CRM land-grab is largely finished. The AI-agent leg (Falcon, Vault AI, Ostro) is a genuine re-acceleration option, but unproven. A $31B name growing 12% is a compounder, not a multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. EPS figures below are non-GAAP (the basis management guides and the Street quotes) unless noted.

Case	Key assumptions	Fair value
Bull	AI agents (Falcon/Vault AI) re-accelerate subscription growth back toward high-teens; Vault R&D keeps compounding. FY28E non-GAAP EPS beats to ~$10.75 (vs ~$10.03 cons); multiple re-rates to ~28× as growth reaccelerates.	~$300 (+56%)
Base (our anchor)	Estimates roughly hit — FY28E non-GAAP EPS ~$10.03; a durable low-teens compounder with 75% GM and net cash earns a ~23× multiple.	~$235 (+22%)
Bear	AI monetization slips, CRM migration friction or a large-customer loss, growth fades toward high-single-digits. FY28E EPS misses to ~$9.25; multiple de-rates to ~16× (where it briefly traded in this drawdown).	~$150 (−22%)

Synthos fair value = the base case, ~$235 (+22%), with the full $150–$300 span as the honest range. Our base coincides almost exactly with the Street's $235.38 consensus — a rare case where our independent model and the sell-side land in the same place, which raises our confidence in the anchor rather than lowering it. Our bear ($150) sits just below the Street's $165 low; our bull ($300) just below the $320 high. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). VEEV is a high-quality compounder that is well past its acceleration phase:

Forward growth: revenue CAGR FY26→FY31E ~12.2% ($3.20B → $5.69B est); non-GAAP EPS CAGR FY27→FY31E ~12.5% ($9.06 → $14.49 est). Solid, not explosive.
Acceleration (the 2nd derivative) is negative: revenue growth was 30%+ in the pandemic-era peak, ~28% in FY22, then decelerated to ~+9% (FY25), and is running ~+16% now (FY26 and Q1 FY27). The Street models it fading further toward ~+12% by the end of the decade. Per our flagship philosophy we favor forward next-exponentials over trailing compounders — VEEV is firmly on the compounder end.
Room to run: at $31B market cap the room is real but not enormous. Veeva's own long-term aspiration has been ~$6B revenue; the broader life-sciences software/AI TAM it now addresses (commercial + R&D + data + AI agents) is arguably $20B+, so demand runway exists — but it has already captured the biggest, easiest customers (1,500+ including the largest pharmas). The next dollars are harder-won.
The one accelerant: AI agents. Falcon (agentic labor for clinical/regulatory/safety) and Vault AI are the only credible path back to high-teens growth. This is unproven and early (Falcon early-adopter release Nov-2026), so it is optionality, not base case — but it is a real, well-positioned option given Veeva's proprietary industry data.

Exponential Potential: Modest (4/10). Own VEEV for durable low-teens compounding at fortress-quality economics, with the AI-agent leg as free-ish optionality — not for a fast multibagger.

5. Financials (real numbers — FMP annual/quarterly)

Revenue: FY26 (Jan-2026) $3.195B, +16.3% (FY25 $2.747B, +16.2% on FY24 $2.364B). Steady mid-teens at scale.
Quarterly trajectory: Q1 FY26 $759M → Q2 $789M → Q3 $811M → Q4 $836M → Q1 FY27 (Apr-2026) $883M (+16.3% YoY). Consistent, no cliff — but no re-acceleration either.
Margins: gross 75.0% TTM, EBITDA margin 39.2% TTM, GAAP operating margin ~29%, net 28.4% TTM. Note: GAAP net margin is depressed by heavy stock-based comp (~3.5% of revenue) and a non-operating drag; non-GAAP operating margin runs ~45% (management guides ~$1,610M non-GAAP op income on ~$3,640M revenue ≈ 44%).
Earnings: GAAP net income $909M FY26 (up from $714M FY25); GAAP EPS $5.55 (diluted $5.44). Q1 FY27 GAAP net income $261M; non-GAAP diluted EPS $2.24 (vs $1.97 a year ago, +14%).
Cash flow: operating CF $1.42B FY26, capex only −$29M (asset-light), FCF ~$1.39B — a ~5.3% FCF yield on today's price and an ~87% FCF/operating-cash conversion. This is the tell of the model's quality: it converts almost all profit to cash.
Balance sheet: cash + short-term investments $6.56B, essentially no financial debt (only ~$96M capital leases), net cash ~$1.3B (net-debt/EBITDA −1.4×), current ratio 4.7. Deferred revenue $1.49B underlines the recurring, prepaid subscription base.

6. Valuation — priced in or room?

VEEV is no longer expensive the way it was at $310. On trailing GAAP it looks rich (33× EPS, 9.4× sales, 22.7× EV/EBITDA), but the forward picture is the point: on management/Street non-GAAP EPS the multiple is ~21× FY27E ($9.05–9.06) → ~19× FY28E ($10.03) → ~15× FY30E ($12.70). For a 75%-gross-margin, net-cash, ~80%-recurring monopoly compounding low-teens, ~21× forward is a defensible, close-to-fair multiple — not a screaming bargain, but no longer the 40–50× the stock carried in its hypergrowth years. The EV/sales of 8.9× is well below its own history. A simple check: the PEG on forward non-GAAP EPS (~21× / ~12% growth ≈ 1.75) is full but not egregious for this quality tier. Street targets (context): consensus $235.38, high $320, low $165; 29 Buy / 13 Hold / 1 Sell; FMP letter rating A-. Our $235 base matches consensus — a quality-compounder-at-a-fair-price, bought after the de-rating.

7. Technicals (from the FMP tech block)

Trend: repairing a downtrend. $192.74 sits above the 50-DMA ($165) but below the 200-DMA ($213) — the classic posture of a stock trying to bottom, not yet confirmed. The 50 below the 200 is still a death-cross overhang.
Location: −37% off the 52-week high ($306), +27% off the 52-week low ($151). Max drawdown from peak −43% — this is a name that fell hard and is early in a recovery attempt.
Momentum: RSI(14) 75 — overbought on the short-term bounce (the day's print was +4.6%). Momentum is hot right now, which argues against chasing the exact print; a pullback toward the rising 50-DMA (~$165–175) would be a lower-risk entry.
Relative strength (the tell): VEEV −31.9% 12-mo vs SPY +20.6% and QQQ +30.3% — massive underperformance over the year, the source of the opportunity. But 3-mo it is +11.6% (vs SPY +13.7%, QQQ +22.0%), so it is recovering, just still lagging.
Read: technicals say early-stage repair after a deep de-rating — consistent with a Tactical (not Core) buy. The overbought RSI is a reason to scale in rather than lump in at $193.

8. Moat & competitive position

Veeva's moat is a rare vertical-SaaS combination: (1) deep industry specificity — software built only for life sciences, embedding pharma-specific regulatory, compliance, and workflow logic a horizontal vendor can't easily replicate; (2) switching costs — CRM, clinical, regulatory, quality, and safety systems are mission-critical and validated under FDA/EMA scrutiny, so ripping them out is expensive and risky; (3) data network effects — OpenData, Link, and Crossix aggregate industry data that improves with scale; and (4) a founder-CEO (Gassner) with a long product-led track record. The FY26 leap in Vault CRM (150+ customers live after leaving the Salesforce platform) shows Veeva can migrate its own base onto its own stack — a moat-deepening move.

Peer set (FMP-listed, market cap): the FMP "peers" list is broad healthcare-tools/services rather than pure software comps — IQVIA $34.6B (the closest real competitor in life-sciences data/analytics/CRO), Agilent $36.9B, Becton Dickinson $57.3B, Cardinal Health $56.0B, IDEXX $44.0B, Edwards Lifesciences $54.3B, GE HealthCare $29.8B, argenx $58.2B, Bruker $9.4B, Haleon $43.3B. IQVIA is the only genuine competitive overlap; the rest are context. Veeva commands a premium multiple and far higher margins than this group, justified by its software economics and monopoly-like position in its niche.

9. Management, capital allocation & guidance

Capital allocation: conservative and shareholder-neutral — asset-light (capex <1% of revenue), no dividend, minimal buyback (net stock issuance is slightly positive due to SBC). The company simply accumulates cash ($6.6B and growing). At this ROIC and with an AI investment cycle underway, hoarding cash is defensible, though at some point capital return becomes a question.
Insider activity: the most recent Form 4s (filed 2026-06-22) are routine director RSU awards (grants, not open-market sales) — no alarming discretionary insider selling in the sampled window. Founder Gassner remains a large holder.
Management's own guidance (the earnings-call track — half-weighted, self-interested): The SEC 8-K (Q1 FY27 release, dated 2026-06-03) is a genuine earnings release with explicit guidance. Management raised FY27 guidance: total revenues $3,635–$3,645M, non-GAAP operating income ~$1,610M, non-GAAP fully-diluted EPS ~$9.05. Q2 FY27 guide: revenue $902–$905M, non-GAAP EPS $2.21–$2.22. CFO Van Wagener: results "exceeded guidance on all metrics… pleased with the raised fiscal 2027 guidance." CEO Gassner framed the AI-agent transition (Ostro live for 50+ brands, Vault AI expanding to all Vault apps in August, Falcon early-adopter release in November). Treat these as management's own book, half-weighted by design — but note the guide was raised and Q1 beat on all metrics, which corroborates the fundamental case.

10. Catalysts & what to watch

Next earnings: 2026-09-02 (Q2 FY27; Street EPS $2.22, revenue ~$905M — right at the top of management's own $902–905M guide). Watch subscription revenue growth (the mid-teens vs re-acceleration question) and any raise to the FY27 outlook.
Veeva Falcon early-adopter release (November 2026): the single biggest swing factor for the exponential/bull case — early customer traction on agentic AI would be the re-acceleration signal.
Vault AI rollout (August 2026): expansion across all Vault apps; adoption/monetization commentary.
Vault CRM migration: continued conversion of the CRM base off the legacy Salesforce platform onto Veeva's own stack (150+ live) — execution here protects the commercial franchise.
Capital-return decision: with $6.6B cash and no debt, any move toward a buyback or dividend would be a new positive.

Thesis tripwires (what would change the call): subscription growth decelerating below ~10% for two consecutive quarters; a large-customer loss or CRM-migration stumble; AI-agent products slipping materially past their release timelines; or the multiple pushing back above ~28× forward without a growth re-acceleration to justify it.

11. Key risks

Growth maturation (the core risk): the CRM land-grab is largely done and the Salesforce-migration tailwind is finite; future growth leans on Vault R&D and unproven AI agents. If those disappoint, mid-teens growth could slip toward high-single-digits, compressing the multiple.
Valuation / de-rating precedent: the stock already fell 43% peak-to-trough; at ~21× forward it is fair, not cheap, so another growth scare could de-rate it again toward the bear's ~16×.
Customer concentration in one industry: Veeva lives or dies with life-sciences IT budgets — biopharma funding cycles, M&A among its customers, and pharma regulatory/pricing policy all flow through to Veeva's demand.
AI as double-edged: agentic AI is Veeva's biggest opportunity and a potential disruptor — a horizontal AI platform or a customer building in-house could, in theory, erode the vertical moat over time.
Thin expert coverage: only 1 KB claim (four years old) — this verdict rests on quant/fundamentals, not a corroborating panel, so it carries less conviction than our broad-breadth names.

12. Verdict, position sizing & monitoring

Buy — Tactical. Veeva is a genuinely elite vertical-SaaS business — 75% gross margin, ~$1.4B FCF, net-cash balance sheet, near-monopoly switching costs, founder-led — that the market has de-rated from ~$310 to $193 as growth normalized from hypergrowth to the mid-teens. At ~21× forward non-GAAP EPS, the quality is finally close to fairly priced, and our independent base-case fair value (~$235) lands right on the Street consensus. What holds this back from Core is honest: growth is decelerating, the KB breadth is a single four-year-old claim (so this is a quant/fundamentals call, not a conviction-panel call), and the technicals show only an early, overbought recovery off a deep drawdown.

Sizing: tactical/satellite, ~2–3% — a quality name bought on a de-rating, not a core anchor. The overbought RSI(14) 75 argues for scaling in (starter now, adds toward the rising 50-DMA ~$165–175) rather than a single lump at the hot print.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with the AI-agent releases (Vault AI August, Falcon November) as the key watch items for a potential Core upgrade. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $192.74.
Single biggest risk: the core CRM base is nearly saturated and the migration tailwind is finite — growth now depends on Vault R&D and unproven AI agents delivering.

Provenance & disclosures

Traceability: 1 KB claim, breadth 1, skill 1.0 (Invest Like the Best), last claim 2022-07-04 — reconciled to a real claim_id (cited inline). This is explicitly a fundamentals/quant-driven verdict; we do not manufacture conviction the KB doesn't contain. Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2026-04-30 (Q1 FY27) · estimates & prices 2026-07-03 · expert claim 2022-07-04. Forward figures are analyst consensus / management guidance (FMP + SEC 8-K), labeled as estimates.
Management caveat: the FY27 guidance in §9 is management's own book (raised outlook, non-GAAP basis), half-weighted by design.
Non-GAAP note: management and the Street quote non-GAAP EPS (which excludes stock-based comp); GAAP EPS is materially lower ($5.55 FY26 vs ~$9 non-GAAP FY27E). Forward P/E figures here are non-GAAP unless labeled otherwise.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").